Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
FDA-approved semaglutide and tirzepatide prescribing information used for general class safety context
The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5 mg tirzepatide group (difference versus placebo 34%
The figures above come from clinical trials, where people are usually monitored closely and given structured lifestyle support alongside medication
Medical Disclaimer CLINICIAN-SUPVISED MEDICAL WEIGHT LOSS MEDICATION SOURCED FROM FDA-REGULATED U.S
US$ 20.43
US$ 23.02
US$ 26.40
US$ 26.87
